Medimmune Limited

Medimmune Vaccines, Inc.

University of Kansas

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Aviron

Hong Jin

Zhongying Chen

George William Kemble

Xing Cheng

Bin Lu

Erich Hoffmann

Martin L Bryant

Roderick Tang

Shengqiang Li

Gregory Duke

Matthew John McCourt

Kanta Subbarao

Hyun Jung Park

Mark Galinski

Danielle Carroll

Erich Hoffman

Greg Duke

Bala Subramaniam

Anindya Ghosh

Jon Tunge

Bin Liu

Jon A Tunge

Marty Bryant

Matthew Mccourt

The present invention provides methods for inducing regression of tumors in human subjects, the methods utilize a modified mesogenic strain of Newcastle disease virus (NDV) with modified F protein cleavage site, which is non-pathogenic to poultry (lentogenic), but exhibits oncolytic properties. The disclosed methods provide safe, effective and reliable means to induce regression of a tumor in an individual in need thereof. These methods overcome the drawbacks of using pathogenic strains of viruses for human therapy.

Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25&#xb0; C. (and immunogenic compositions comprising the same) is also provided.

Multi plasmid system for the production of influenza virus

Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.

Influenza hemagglutinin and neuraminidase variants

The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection.

Influenza B viruses having alterations in the hemagglutinin polypeptide

The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.

Swine influenza hemagglutinin variants

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.

Influenza B viruses having alterations in the hemaglutinin polypeptide

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics.

The complete polynucleotide sequence of the human respiratory syncytial virus subgroup B strain 9320 genome is provided. Proteins encoded by this polynucleotide sequence are also provided. Isolated or recombinant RSV (e.g., attenuated recombinant RSV), nucleic acids, and polypeptides, e.g., comprising mutations in the attachment protein G, are also provided, as are immunogenic compositions comprising such isolated or recombinant RSV, nucleic acids, and polypeptides. Related methods are also described.

Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320

Method for producing temperature sensitive influenza A viruses

In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza viruses with increased replication capacity, and immunogenic and vaccine compositions comprising such recombinant and/or reassortant influenza viruses. In other aspects, the invention further provides nucleic acids encoding influenza genes associated with increased replication capacity, expression vectors comprising the nucleic acids of the invention, methods for making influenza viruses with increased replication capacity, and kits useful for practice of the methods.

Growing community of inventors

Cupertino, CA, United States of America

Hong Jin